Embed Size (px)
Citation preview
ContosoPharmaceuticals
LUCYCHANGING THE CANCER
DIAGNOSTIC LANDSCAPE
ContosoPharmaceuticals
The ProblemHOW TO DETECT CANCERS EARLY WHEN
LESS DANGEROUS AND MORE TREATABLE
Size matters - tumour size is stronglyrelated to prognosis
Imaging modalities are incapable of detecting truly early cancers
Early stage cancers are difficult to detect even in a screening programme
Successful treatment and survival is much higher when the tumour is detected early
ContosoPharmaceuticals
LUCY CANCERBLOODTEST
LUCY is a new tissue of origin cancer blood test under
development, based on the detection of a novel biomarker that is
expressed exclusively by malignant cancer cells. NOTE Until testing
is completed, the diagnostic test statements are projections only.
LUCY is a highly sensitive blood test that can detect cancers as
small as 1 - 2mm diameter with over 99% sensitivity. Cancers this
small are undetectable by other modalities, and in order to ‘see’ small cancers, AI is used to calculate tumour size at point of analysis.
You can then uniquely stage these early cancers and know if/when
they are large enough to be visible within imaging modalities.
. Main test features:
• Tissue of origin test
• Detects cancers as small as 1 - 2mm size
• Over 99% sensitivity
• Uses AI to reveal tumour size
• Conclusive evidence for malignant cancers
• Allows tumour monitoring
• Almost zero false positives
• Fast turnaround laboratory test
ContosoPharmaceuticals
LUCY AS CANCER SCREENING TEST
• LUCY is a new whole body tissue of origin cancer blood test
under development, designed to replace existing screening
tests for breast cancer (mammography) lung cancer (PET/CT)
and prostate cancer (MRI +PSA).
• BREAST CANCER: LUCY can detect breast cancers when
only 1-2mm size, with over 99% sensitivity. LUCY uses AI to
calculate the size of tumours that would be undetectable by
mammography and is revealed at point of analysis as part of
the test process.
• LUCY can conclusively determine if tumours are malignant
without requiring a confirmatory tissue biopsy. LUCY can
peerlessly monitor women having the mutated BRCA gene, to
help prevent unnecessary prophylactic surgery.
• LUCY can monitor cancers using test snapshots to know
which breast cancers are triple negative and require
treatment, and which cancers can disappear without needing
any treatment. LUCY can screen women of any age as breast
tissue density is not an issue.
• LUCY will also screen for other cancers in one test to confirm if cancer free.
ContosoPharmaceuticals
LUCY AS CANCER SCREENING TEST
• LUNG CANCER: The standard method of detection for lung
cancer is by PET/CT that can detect 7 mm diameter tumours,
but still need a tissue biopsy to confirm if malignant. LUCY
can detect lung cancers when 1-2 mm diameter size, being
well below the limits of detection of imaging modalities, but
doesn’t require a tissue biopsy as a positive LUCY test is
conclusive evidence of malignancy. LUCY uses AI to
accurately measure the size of a detected tumour at point of
analysis, to reveal if large enough to be seen by imagery, and
also to stage the cancer. LUCY is a tissue of origin cancer test
and will screen the whole body for other cancers in one test.
PROSTATE CANCER: LUCY is a highly sensitive cancer blood
test able to detect prostate cancer when undetectable by
imaging modalities. LUCY can detect prostate cancers when
just 1 – 2 mm in size with 99% sensitivity, and using AI the size
is revealed at point of analysis so that the data can be used
clinically. LUCY can be used to take test snapshots once a
cancer has been found to determine if the tumour is
progressing and how fast. A positive LUCY test is conclusive
evidence that a detected tumour is malignant and not benign,
so a confirmatory tissue biopsy is not required. LUCY screens
the whole body for other cancers in one test.
ContosoPharmaceuticals
LUCYA NEXT GENERATION CANCER BLOOD TEST UNDER DEVELOPMENT
BLOOD TEST
Lucy is a tissue of origin
blood test.
BIOPSY
LUCY is a liquid biopsy able to confirm cancers at the lowest known level of detection
LUCY can link to an AI hub containing
historic treatment cases to help
produce best practice therapy
strategies
FALSE POSITIVES
Almost zero false positives
ARTIFICIAL INTELLIGENCE
Measures cancer size to stage and reveal if large enough to be seen in imaging modalities
AUTOMATED THERAPY
ContosoPharmaceuticals
LUCYA NEXT GENERATION CANCER BLOOD TEST UNDER DEVELOPMENT
SENSITIVITY
LUCY detects 1-2 mm cancers with 99% sensitivity
WHOLE BODY
LUCY screens the whole body for all cancers
CONFIRMATION
LUCY confirms if cancer free, to lowest known limit of detection
CLOSING A DIAGNOSTIC VOID
LUCY detects small cancers that are undetectable by imaging modalities
PATENTED PROCESS
LUCY uses unique processes that are subject to provisional patent applications
ContosoPharmaceuticals
THE GLOBAL CANCER DIAGNOSTIC MARKET 2020
• The global cancer diagnostic market is segmented on
the basis of technology, application and region.
• The cancer diagnostics market is categorized into
platform-based and instrument-based, encompassing
ELISA, ELFA, PCR, NGS, Immunohistochemistry,
Microarray, Imaging (MRI, CT, PET, Ultrasound,
Mammography, Biopsy), by application (Breast Cancer,
Lung Cancer, Colorectal Cancer, Melanoma).
• Breast cancer application is expected to account for a
major share of the cancer diagnostics market by
application in 2018.
• In total, the cancer diagnostics market’s worth is
predicated to be $13.1 billion by 2020.
Source: Market and Markets
ContosoPharmaceuticals
MARKET POSITION FOR LUCYCANCER BLOOD TEST
.
• LUCY is a unique cancer blood test because it operates in an invisible diagnostic world ,that exists below the limits of detection of imaging modalities. This is because LUCYcan detect cancers pre angiogenesis, when cancer cells before tumour formation; where imaging modalities have a detection limit starting above 7 mm diameter tumours.
The problem of how to visualise invisible cancers has been resolved by the use of AI, where cancers in the range of 2mm – 10mm are accurately measured for size at point of analysis. Sizing also confirms if a cancer is large enough to be seen within imaging modalities.
• The ambition for LUCY is to replace all imaging tests for cancer detection, as the first test choice. This includes screening programs for, breast, lung and prostate cancers, and proposed whole body screens, having a wider appeal in detecting asymptomatic cancers.
ContosoPharmaceuticals
LUCYCANCER BLOOD TEST COMPARISON
CANCER BLOOD TEST COMPARISON
The LUCY cancer blood test will reliably detect cancers when
just 1 -2 mm diameter and uses AI to calculate their size at the
point of analysis, to stage the cancer, and reveal if large
enough to be visible within a scan. A 1mm-2mm sized tumour
contains between 100,000 – 400,000 cancer cells, and if a
breast cancer, has less than 1% chance of progressing.
By comparison, blood tests based on cell free circulating
tumour DNA are unable to detect cancers below 1cm diameter
size because there is not enough DNA material available to
analyse. A 1cm sized tumour contains about 50 million cancer
cells, and if a breast cancer, has a 50% chance of progressing.
This comparison shows that blood tests based on tumour DNA
detection are incapable of detecting small cancers and would
produce a false negative result in every test when a tumour
exists with a size below 1cm Most imaging modalities could
themselves detect .these missed cancers, anyway..
ContosoPharmaceuticals
LUCY TEST DEVELOPMENT
National Physical Laboratory | Hampton Road
Teddington, Middlesex | UK | TW11 0LW
University of Surrey ( PROVISIONAL)
Guildford
Surrey GU2 7XH
ContosoPharmaceuticals
CONTACT DETAILS
Gino Francesco
Specialist Cancer Screening Ltd
21 Botanic Place
Edge Hill
Liverpool
L7 OER
United Kingdom
Registered office
CONTACT:
07925 350088
Copyright Specialist Cancer Screening Ltd 2019
ContosoPharmaceuticals
LUCY IS FOR ANIMALS TOO
ContosoPharmaceuticals
LUCY
